Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker, S.R., Barlow, C., Martin, M.P., Mancusi, C., Wagner, S., Self, A., Barrie, E., Te Poele, R., Sharp, S., Brown, N., Wilson, S., Jackson, W., Fischer, P.M., Clarke, P.A., Walton, M.I., McDonald, E., Blagg, J., Noble, M., Garrett, M.D., Workman, P.(2018) Mol Oncol 12: 287-304
- PubMed: 29063678 
- DOI: 10.1002/1878-0261.12148
- Primary Citation of Related Structures:  
5MHQ - PubMed Abstract: 
Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer. We describe herein the molecular and cellular effects of CCT068127, a novel inhibitor of CDK2 and CDK9 ...